Patient adherence to ultrasound liver cancer surveillance recs is low
Patient adherence to ultrasound hepatocellular carcinoma (HCC) surveillance imaging recommendations has been suboptimal, according to research published January 12 in Radiology: Imaging Cancer.Ultrasound is considered a cost-effective surveillance method in the management of HCC, a common type of liver cancer associated with long-term liver damage and scarring of the liver and chronic infections such as hepatitis B and hepatitis C, a research team from the University of California, San Francisco (UCSF) noted. But whether patients comply with surveillance recommendations prompted by the ultrasound LI-RADS metric isn't cle...
Source: AuntMinnie.com Headlines - January 16, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
Clinical Breast Exam Rarely Detects Second Breast Cancer After DCIS
FRIDAY, Jan. 12, 2024 -- For patients undergoing surveillance following diagnosis and treatment of ductal carcinoma in situ (DCIS), very few second breast cancers are detected by clinical breast examination by a physician, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 12, 2024 Category: Pharmaceuticals Source Type: news
Community Cancer Centers Treating More HPV-Related Head, Neck Cancer
THURSDAY, Jan. 11, 2024 -- Treatment of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma has recently shifted to community cancer centers, with an increase in the proportion of nonsurgical treatment and worse overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2024 Category: Pharmaceuticals Source Type: news
Clinical Exams Fall Short in Second Breast Cancer Detection Clinical Exams Fall Short in Second Breast Cancer Detection
A decade-long surveillance study shows clinical breast examinations are largely ineffective in detecting second cancers in women treated for ductal carcinoma in situ.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
The common skin cancer that could turn into deadly melanoma- as President Joe Biden shows off sunburned skin on return from Caribbean vacation less than a year after having cancerous lesion removed
President Joe Biden has already been warned off being burnt, after suffering basal cell carcinoma - a type of skin cancer - in February last year and several other bouts of the cancer before 2021. (Source: the Mail online | Health)
Source: the Mail online | Health - January 3, 2024 Category: Consumer Health News Source Type: news
No Added Benefit From Chemo in This Breast Cancer Subtype No Added Benefit From Chemo in This Breast Cancer Subtype
Adding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma does not improve survival outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
LI-RADS shows low NPV in per-patient liver tumor assessment
Per-patient grouping for liver tumor status based on LI-RADS and treatment response shows low negative predictive value (NPV) in detecting residual or untreated tumors, according to research published December 19 in Radiology. A team led by Omar Hassan, MD, from the University of California, San Francisco studied hepatocellular carcinoma (HCC) patients who underwent local-regional therapy followed by liver transplant. The team found that per-patient stratification of tumor status at either pretransplant CT or MRI based on the LI-RADS version 2018 treatment response algorithm showed low NPV in this area. “The relativel...
Source: AuntMinnie.com Headlines - December 20, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: MRI Abdominal Imaging Source Type: news
Telix submits PET tracer for FDA review
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its clear cell renal cell carcinoma PET radiotracer TLX250-CDx (Zircaix).The PET tracer has been granted a rolling review process under the FDA’s Breakthrough Therapy designation, which will enable a progressive submission and review of required modules in a timeframe agreed upon with the FDA, the company said. It has also requested priority review.In addition, Telix said it has opened an expanded access program in the U.S. and a named-patient program in Europe to allow access to Zircaix outside of...
Source: AuntMinnie.com Headlines - December 19, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Risk for Skin Cancer Increased for Patients With Lower Extremity Lymphedema
MONDAY, Dec. 18, 2023 -- Patients with lower extremity (LE) lymphedema have an increased risk for skin cancer, especially basal cell carcinoma, according to a study published online in the November issue of Mayo Clinic Proceedings.Nimay C. Anand,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2023 Category: Pharmaceuticals Source Type: news
Belzutifan Approved for Advanced Renal Cell Carcinoma Belzutifan Approved for Advanced Renal Cell Carcinoma
The FDA approval makes belzutifan the first agent specifically indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
(MedPage Today) -- The FDA approved belzutifan (Welireg) for previously treated advanced renal cell carcinoma (RCC), the agency announced on Thursday.
Belzutifan is indicated for RCC patients with disease progression after a PD-1/L1 checkpoint... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 15, 2023 Category: American Health Source Type: news
FDA Approves Merck ’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news
FDA approves belzutifan for advanced renal cell carcinoma
On December 14, 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck& Co., Inc.) for patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
